Abstract
The mammalian target of rapamycin complex 1 syndrome (Tors), paradigm implies an exhaustive cohesive disease entity driven by a hyperactive mTORC1, and which includes obesity, type 2 diabetic hyperglycemia, diabetic dyslipidemia, diabetic cardiomyopathy, diabetic nephropathy, diabetic peripheral neuropathy, hypertension, atherosclerotic cardiovascular disease, non-alcoholic fatty liver disease, some cancers, neurodegeneration, polycystic ovary syndrome, psoriasis and other. The TorS paradigm may account for the efficacy of standard-of-care treatments of type 2 diabetes (T2D) in alleviating the glycaemic and non-glycaemic diseases of TorS in T2D and non-T2D patients. The TorS paradigm may generate novel treatments for TorS diseases.
| Original language | English |
|---|---|
| Article number | e3712 |
| Journal | Diabetes/Metabolism Research and Reviews |
| Volume | 40 |
| Issue number | 1 |
| DOIs | |
| State | Published - Jan 2024 |
Bibliographical note
Publisher Copyright:© 2023 The Authors. Diabetes/Metabolism Research and Reviews published by John Wiley & Sons Ltd.
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- insulin
- mTORC1syndrome (TorS)
- metabolic stress
- metabolic syndrome (MetS)
- type 2 diabetes (T2D)
Fingerprint
Dive into the research topics of 'TorS - Reframing a rational for type 2 diabetes treatment'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver